Real-World Reintervention Rates Among TAVR Low-Risk Medicare Patients with Dr. Robert Yeh and Dr. Matthew Summers

As TAVR expands into younger and lower-risk patients, one question continues to drive decision-making: how durable are transcatheter valves over time?In this MurmurMD discussion, Dr. Robert W. Yeh reviews his late-breaker at CRT26, the Evolut valve durability data, focusing on long-term outcomes and what they mean for real-world clinical practice with Dr. Matthew Summers.Key insights from the transcript include:• Long-term performance of self-expanding Evolut valves• How durability is assessed and measured over time• Structural valve degeneration and clinical relevance• Comparing durability expectations in TAVR vs surgical valves• Patient selection and lifetime management considerations• What durability data means for younger TAVR patients• How evolving evidence may shape future practiceThis discussion provides a focused look at how durability data is influencing TAVR decision-making today and into the future.🔔 Subscribe for more insights from interventional experts and real-world program builders.📱 Download the app: https://apps.apple.com/app/apple-store/id1586692687📺 Follow us on YouTube: https://www.youtube.com/channel/UCfrLYhAhliQ2ZvXinkDCZvAChapters:00:00 – Why valve durability matters in TAVR 01:00 – Overview of Evolut durability data 02:30 – Structural valve degeneration and outcomes 04:30 – Comparing TAVR vs surgical durability 06:00 – Clinical implications for patient selection 07:30 – Key takeaways and future direction#TAVR #Evolut #ValveDurability #StructuralHeart #AorticStenosis #InterventionalCardiology #MurmurMD